Scale with ease as needs change.
The onset of the COVID-19 global pandemic in early 2020 marked the start of a dramatic pivot in clinical diagnostic assay development, and in patient sample collection and processing. As vaccination programmes roll out, diagnostic assay developers and testing labs need to remain vigilant in accommodating the evolving needs of the public health crisis as well as ongoing demand for patient screening for a wide breadth of conditions.
Throughout the COVID-19 pandemic, Biosearch Technologies demonstrated a unique ability to serve the diagnostic community as a reliable mission-critical component supplier. Explore how we can help your organisation manage today while planning for tomorrow.
Optimise your PCR-based testing infrastructure to meet current and future infectious disease detection needs.
Plan ahead to see how you can expand services as demands for PCR-based pathogen detection evolve.
Develop your game plan for In Vitro Diagnostic Regulation (IVDR) compliance.
We have the expertise to leverage our flexible manufacturing platform to deliver according to your specifications and throughput, yielding a product that produces repeatable and consistent performance. Our comprehensive portfolio grants our customers unparalleled freedom for customisation that’s coupled with a hands-on team to help bring your ideas and aspirations to life.
6 tips for early-stage molecular diagnostics companies to commercialise.
What to look for in a reliable molecular diagnostic supplier
How our oligo synthesis team contributes to the reliability of your assays.
| Europe, Middle East, and Africa | |
|---|---|
| UK | +44 1992 470 757 |
| Germany | +49 30 1663 54600 |
| North America, Latin America | |
| Wisconsin, USA | +1 888 575 9695 |
| Asia Pacific | |
| China | +8621-22509000 |
| Singapore | +65 6734 4800 |
